Literature DB >> 19961812

Guideline update: what's the best approach to acute low back pain?

Son M Bach1, Keith B Holten.   

Abstract

GRADE A RECOMMENDATIONS (based on good-quality patient-oriented evidence): Advise patients to stay active and continue ordinary activity within the limits permitted by pain, avoid bed rest, and return to work early, which is associated with less disability. Consider McKenzie exercises, which are helpful for pain radiating below the knee. Recommend acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs) if medication is necessary. COX-2 inhibitors, muscle relaxants, and opiate analgesics have not been shown to be more effective than NSAIDs for acute low back pain. Consider imaging if patients have no improvement after 6 weeks, although diagnostic tests or imaging is not usually required. GRADE B RECOMMENDATIONS (based on inconsistent or limited-quality patient-oriented evidence): Reassure patients that 90% of episodes resolve within 6 weeks-regardless of treatment. Advise patients that minor flares-ups may occur in the subsequent year. Consider a plain lumbosacral spine x-ray if there is suspicion of spinal fracture or compression. Consider a bone scan after 10 days, if fracture is still suspected or the patient has multiple sites of pain. Suspect cauda equina syndrome or severe or progressive neurological deficit if red flags are present. Obtain complete blood count, urinalysis, and sedimentation rate if cancer or infection are possibilities. If still suspicious, consider referral or perform other studies. Remember that a negative plain film x-ray does not rule out disease. GRADE C RECOMMENDATIONS (based on consensus, usual practice, opinion, disease-oriented evidence, or case series): Recommend ice for painful areas and stretching exercises. Discuss the use of proper body mechanics and safe back exercises for injury prevention. Refer for goal-directed manual physical therapy if there is no improvement in 1 to 2 weeks, not modalities such as heat, traction, ultrasound, or transcutaneous electrical nerve stimulation. Do not refer for surgery in the absence of red flags.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19961812

Source DB:  PubMed          Journal:  J Fam Pract        ISSN: 0094-3509            Impact factor:   0.493


  6 in total

1.  A decade's experience in lumbar spine surgery in Belgium: sickness fund beneficiaries, 2000-2009.

Authors:  Marc Du Bois; Marek Szpalski; Peter Donceel
Journal:  Eur Spine J       Date:  2012-06-03       Impact factor: 3.134

2.  The Global Spine Care Initiative: a systematic review for the assessment of spine-related complaints in populations with limited resources and in low- and middle-income communities.

Authors:  Margareta Nordin; Kristi Randhawa; Paola Torres; Hainan Yu; Scott Haldeman; O'Dane Brady; Pierre Côté; Carlos Torres; Michael Modic; Rajani Mullerpatan; Christine Cedraschi; Roger Chou; Emre Acaroğlu; Eric L Hurwitz; Nadège Lemeunier; Jean Dudler; Anne Taylor-Vaisey; Erkin Sönmez
Journal:  Eur Spine J       Date:  2018-02-28       Impact factor: 3.134

3.  The efficacy of thermotherapy and cryotherapy on pain relief in patients with acute low back pain, a clinical trial study.

Authors:  Morteza Dehghan; Farinaz Farahbod
Journal:  J Clin Diagn Res       Date:  2014-09-20

Review 4.  Arm ache.

Authors:  Hosein Ahmadzadeh Chabok; David Ring
Journal:  Hand (N Y)       Date:  2014-06

5.  The effect of the stay active advice on physical activity and on the course of acute severe low back pain.

Authors:  Patricia Olaya-Contreras; Jorma Styf; Daniel Arvidsson; Karin Frennered; Tommy Hansson
Journal:  BMC Sports Sci Med Rehabil       Date:  2015-08-27

6.  Effects of eye movement desensitization and reprocessing (EMDR) on non-specific chronic back pain: a randomized controlled trial with additional exploration of the underlying mechanisms.

Authors:  Jonas Tesarz; Andreas Gerhardt; Sabine Leisner; Susanne Janke; Mechthild Hartmann; Günther H Seidler; Wolfgang Eich
Journal:  BMC Musculoskelet Disord       Date:  2013-08-30       Impact factor: 2.362

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.